DJIA53377.41 -308.70
S&P 5007667.88 36.41
NASDAQ26476.62 -107.44
Russell 20002972.48 4.21
German DAX25908.78 69.45
FTSE 10010758.15 1.70
CAC 408260.12 -20.51
EuroStoxx 506362.05 -0.80
Nikkei 22565020.94 806.46
Hang Seng25188.00 -123.21
Shanghai Comp3942.09 0.70
KOSPI6687.21 107.73
Bloomberg Comm IDX142.78 -0.36
WTI Crude-fut91.72 0.07
Brent Crude-fut90.75 -0.83
Natural Gas2.97 0.04
Gasoline-fut3.18 0.03
Gold-fut4485.60 -34.70
Silver-fut66.82 -0.72
Platinum-fut1830.00 0.90
Palladium-fut1409.00 -24.00
Copper-fut6.69 0.09
Aluminum-spot3195.00 0.00
Coffee-fut298.10 -11.35
Soybeans-fut1310.50 -4.00
Wheat-fut748.75 -3.50
Bitcoin79488.79 -1719.09
Ethereum USD2455.48 -39.93
Litecoin50.28 -1.08
Dogecoin0.09 0.00
EUR/USD1.1625 0.0023
USD/JPY155.46 -3.29
GBP/USD1.3519 0.0016
USD/CHF0.8081 -0.0055
USD IDX99.08 0.08
US 10-Yr TR4.761 -0.001
GER 10-Yr TR3.338 -0.0003
UK 10-Yr TR5.1303 -0.0063
JAP 10-Yr TR2.905 -0.001
Fed Funds3.75 0
SOFR3.66 0.01
High-rise commercial buildings

Sub Markets

Topics

Latest News  + Alternative Assets  | 
Blackstone Closes Record $6.3B Life Sciences Fund

Blackstone Closes Record $6.3B Life Sciences Fund

Blackstone has closed its oversubscribed Blackstone Life Sciences VI (BXLS VI) fund at a $6.3 billion hard cap, making it the firm’s largest life sciences-focused fund to date and nearly 40% larger than its predecessor. 

Since launching its dedicated life sciences platform in 2018, Blackstone has grown BXLS to approximately $15 billion in assets under management as of the fourth quarter of 2025. The platform has supported the development and commercialization of therapies and devices, including LEQVIO, AMVUTTRA, IMBRUVICA and the MiniMed Flex system. 

“Our partnerships with global leaders have produced 34 regulatory approvals of innovative medicines and devices,” said Nicholas Galakatos, Ph.D., Global Head of Blackstone Life Sciences. “This track record highlights how we work successfully with industry trailblazers to help bring their most important products to patients around the world.” 

Over the past 12 months, BXLS has committed nearly $2 billion in new investments, underscoring continued deployment activity. 

Read More News Stories About: Blackstone
Connect

Inside The Story

Blackstone Life Sciences

About Joe Palmisano

Joe Palmisano is editorial director of Connect Money, where he oversees daily coverage of alternative assets, direct investments, financial advisory and the economy. He brings three decades of experience as a financial journalist, analyst and portfolio manager. Before joining Connect Money, Palmisano wrote for The Wall Street Journal, covering foreign exchange, global fixed-income and equity markets. He later served as a senior research analyst and portfolio manager, producing market analysis and managing foreign exchange and U.S. equity portfolios for FX Concepts. His work has also appeared in SFO Magazine and CMT Association publications. Palmisano earned a bachelor’s degree in finance from The American University and holds the Chartered Market Technician (CMT) designation and is a member of the CFA Institute.